MedTrace Logo

Performance of the Travoprost Intraocular Implant

NCT06582732 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2024-10-15

Study results available
· View outcomes & findings →

Summary

To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months

Conditions

Interventions

DRUG

Travoprost Intracameral Implant exchanged at Month 12

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12

DRUG

Travoprost Intracameral Implant exchanged at Month 3

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3

DRUG

Travoprost Intracameral Implant exchanged at Month 6

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6

DRUG

Travoprost Intracameral Implant exchanged at Month 24

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24

DRUG

Travoprost intracameral implant exchanged at Month 21

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21

DRUG

Travoprost intracameral implant exchanged at Month 18

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18

DRUG

Travoprost intracameral implant exchanged at Month 15

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Kerry Stephens · Glaukos Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2023-11-02
Completion
2023-11-02
FDA Drug
Yes

Countries

  • Armenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582732 on ClinicalTrials.gov